Rep. Jonathan L. Jackson Purchases Shares of Guardant Health, Inc. (NASDAQ:GH)

Representative Jonathan L. Jackson (Democratic-Illinois) recently bought shares of Guardant Health, Inc. (NASDAQ:GH). In a filing disclosed on October 19th, the Representative disclosed that they had bought between $15,001 and $50,000 in Guardant Health stock on September 28th. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $50,001 – $100,000 in shares of Estee Lauder Companies (NYSE:EL) on 9/28/2026.
• Sold $50,001 – $100,000 in shares of Viasat (NASDAQ:VSAT) on 9/28/2026.
• Sold $50,001 – $100,000 in shares of Walmart (NASDAQ:WMT) on 9/28/2026.
• Purchased $50,001 – $100,000 in shares of Datadog (NASDAQ:DDOG) on 9/28/2026.
• Sold $1,001 – $15,000 in shares of Tortoise Energy Infrastructure (NYSE:TYG) on 9/4/2026.
• Sold $1,001 – $15,000 in shares of Viasat (NASDAQ:VSAT) on 8/28/2026.

Guardant Health Stock Up 3.0%

Shares of GH stock opened at $162.59 on Wednesday. Guardant Health, Inc. has a twelve month low of $66.59 and a twelve month high of $191.05. The stock’s fifty day simple moving average is $167.70 and its 200 day simple moving average is $140.50. The firm has a market capitalization of $21.82 billion, a P/E ratio of -46.59 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) earnings per share. As a group, equities research analysts expect that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.

Insider Activity

In related news, insider Chris Freeman sold 63,605 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the sale, the insider directly owned 65,374 shares in the company, valued at approximately $11,086,122.92. This represents a 49.31% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 46,300 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 178,940 shares of company stock valued at $30,070,911. 5.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently bought and sold shares of the stock. Englebert Financial Advisers LLC purchased a new stake in Guardant Health in the 3rd quarter worth about $976,000. Nisa Investment Advisors LLC raised its stake in Guardant Health by 364.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 12,895 shares of the company’s stock valued at $2,300,000 after acquiring an additional 10,121 shares during the period. Diversify Advisory Services LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $292,000. Fairvoy Private Wealth LLC purchased a new stake in Guardant Health during the third quarter valued at about $1,271,000. Finally, Jackson Square Capital LLC purchased a new stake in Guardant Health during the third quarter valued at about $451,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

GH has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and issued a $195.00 price objective on shares of Guardant Health in a research note on Wednesday, September 2nd. Piper Sandler reissued an “overweight” rating on shares of Guardant Health in a research note on Tuesday, September 15th. Barclays upped their price target on Guardant Health from $200.00 to $220.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Mizuho upped their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, UBS Group lifted their price target on shares of Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $190.00.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. He declared candidacy for the 2026 election.

Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.